Stem Cell Mobilization and Autograft Purity with Novel Induction Regimens in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2019 at "Biology of Blood and Marrow Transplantation"
DOI: 10.1016/j.bbmt.2018.12.092
Abstract: Background High-dose chemotherapy and autologous stem cell transplantation (ASCT) remains the standard-of-care in transplant-eligible patients with multiple myeloma (MM). Bortezomib with lenalidomide and dexamethasone (RVD) is the most common triplet induction regimen for patients with… read more here.
Keywords: rvd; stem cell; krd; cell ... See more keywords
Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Haematology"
DOI: 10.1111/bjh.18432
Abstract: Patients with multiple myeloma are at increased risk of vascular thromboembolic events (VTEs). This post hoc analysis evaluated VTEs in the randomised phase 2 GRIFFIN study (ClinicalTrials.gov Identifier: NCT02874742) that investigated lenalidomide/bortezomib/dexamethasone (RVd) ± daratumumab (D). Patients… read more here.
Keywords: griffin study; rvd; lenalidomide bortezomib; rvd rvd ... See more keywords
Pulmonary hypertension and right ventricular involvement in hospitalised patients with COVID-19
Sign Up to like & getrecommendations! Published in 2020 at "Heart"
DOI: 10.1136/heartjnl-2020-317355
Abstract: Objective To assess the prevalence, characteristics and prognostic value of pulmonary hypertension (PH) and right ventricular dysfunction (RVD) in hospitalised, non-intensive care unit (ICU) patients with coronavirus disease 2019 (COVID-19). Methods This single-centre, observational, cross-sectional… read more here.
Keywords: rvd; pulmonary hypertension; hypertension right; right ventricular ... See more keywords
Clinical Outcomes of Non-Traditional Lenalidomide, Bortezomib, and Dexamethasone Regimens in Multiple Myeloma
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-143385
Abstract: Introduction Lenalidomide, bortezomib, and dexamethasone (RVD) is a standard first-line regimen for patients with newly diagnosed multiple myeloma and is associated with high response rates and improvement in progression-free survival and overall survival compared to… read more here.
Keywords: lite; rvd lite; rvd; ultra lite ... See more keywords
Real-World Treatment Outcomes in Patients with Newly Diagnosed Multiple Myeloma Treated with Triplet Therapy without Stem Cell Transplant: An Enhanced Electronic Health Records Database
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2190.2190
Abstract: BACKGROUND Recently, utilization of triplet regimens featuring 2 novel agents, such as lenalidomide, bortezomib, and dexamethasone (RVd), has increased in multiple myeloma (MM). RVd as well as cyclophosphamide, bortezomib, and dexamethasone (CyBord) are the most… read more here.
Keywords: research; rvd; treatment; research funding ... See more keywords